GHK-Cu/Estriol/Niacinamide/Tretinoin
Anti-Aging
/
Cream
/
Topical
No items found.
No items found.
Sirolimus
*
Sirolimus, or rapamycin, is an mTOR inhibitor that induces catabolic processes. It has been shown to extend lifespan in several organisms, and notably is one of a handful of substances in NIH's Interventions Testing Program to have the ability to slow down aging. It mediates its effects by inducing autophagy in cells and preventing cells from becoming senescent, whereby they become dysfunctional and spew pro-inflammatory factors that damage neighboring cells. It shows promise in slowing numerous diseases of aging.
ACTIVE INGREDIENTS
Sirolimus (Rapamycin)
HOW TO USE
Usual Dose
Oral (Acid Resistant Capsule): 1mg to 6mg one time by mouth weekly.
- Low intermittent or pulse dosing minimizes adverse effects and may confer immunomodulatory benefits
- Dose varies based on individual needs and health conditions
Topical : Sirolimus 0.001% cream . Apply to skin at night.
- Studies suggest low concentration sufficient for localized anti-aging effects
- Not absorbed systemically. Favorable safety profile.
DISCLAIMER
This compounded medication is only available when the commercially available product is unavailable or when a prescriber determines that there is a clinically significant difference for the patient.
Medicine Information
Potential Benefits
Sirolimus may extend lifespan and notably is one of a handful of substances in NIH's Interventions Testing Program to show longevity benefits in mice. It may slow the progression of numerous diseases linked to the aging process such as:
- Alzheimer’s disease
- Artherosclerosis
- Glaucoma,
- Diabetes
- Chronic kidney disease
- Cancers of various types.
Treament Protocol
Legal
Storage Instructions
Warnings
Possible side effects on a low dose anti-aging pulse-dose regimen:
- Mouth ulcers
- Facial acneiform rash
- Stomach upset
Precaution
- Avoid use if one has an active infection or is on other immunosuppressive therapies
Manufacturer Info
How It Works
Sirolimus inhibits the mammalian target of rapamycin (mTOR), a growth signaling pathway. This induces autophagy, process which degrades and recycle a cell's dysfunctional cellular components, thereby keeping the cell viable and functional. It is crucial for maintaining cellular health by removing damaged organelles, misfolded proteins, and other cellular debris. Sirolimus also inhibits "geroconversion", a process responsible for transforming an aging cell in an arrested state into a senescent cell. Senescent cells have ceased dividing and spew inflammatory factors harming healthy neighboring cells. Sirolimus both slows down the generation of senescent cells, and makes existing senescent cells less harmful by decreasing their pro-inflammatory activity. Through these mechanisms, sirolimus may confer longevity benefits and slow down the progression of multiple age-related diseases.
F.A.Q
Q. Will taking sirolimus suppress my immune system?
A. Sirolimus is an immunosuppressant at doses used for organ transplants. However, at low pulsatile doses (weekly), sirolimus has distinctly different pharmacological effects and behaves as an immunomodulator. In one study, elderly patients who had been on a sirolimus anti-aging dose regimen had a better response to the flu vaccine than those who did not use sirolimus. Sirolimus at these doses may also enhance some immune functions such as the body's ability to surveil and neutralize cancerous cells. Out of a surfeit of caution, those with active infections should avoid sirolimus.
References
1. Blagosklonny MV. Geroconversion: irreversible step to cellular senescence. Cell Cycle. 2014;13(23):3628-35. doi: 10.4161/15384101.2014.985507. PMID: 25483060; PMCID: PMC4614001.
2. Cayo A, Segovia R, Venturini W, Moore-Carrasco R, Valenzuela C, Brown N. mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership. Int J Mol Sci. 2021 Jul 29;22(15):8149. doi: 10.3390/ijms22158149.
3. Kaeberlein TL, Green AS, Haddad G, Hudson J, Isman A, Nyquist A, Rosen BS, Suh Y, Zalzala S, Zhang X, Blagosklonny MV, An JY, Kaeberlein M. Evaluation of off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023 Oct;45(5):2757-2768. doi: 10.1007/s11357-023 00818-1.
4. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892. PMID: 25540326.
